Resumen de: WO2023001919A1

The present invention relates to the use of extracts from Boswellia species and pharmaceutical compositions comprising Boswellia extracts in the treatment of SARS-CoV-2 infection and related medical conditions.

Resumen de: WO2023001259A1

A recombinant multivalent novel coronavirus trimer protein vaccine capable of inducing broad-spectrum and neutralizing activity. The recombinant protein component comprises, but is not limited to, a homotrimer protein formed by introducing, into an extracellular domain (ECD) of B.1.617.1 strain and B.1.617.2 strain spike (S) proteins, a mutation site and a trimerization assistance structure. The multivalent vaccine comprises an ECD trimer protein of a single component or any combination of components of the variant strains above, and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, and can maintain long-term humoral immunity and cellular immunity. The multivalent novel coronavirus trimer protein vaccine can be used for preventing infection-related diseases caused by infection of novel coronavirus and variant strains thereof.

Resumen de: WO2023000403A1

A Sars-Cov-2 subprotein nano-vaccine, and a preparation method therefor and an application thereof. The nano-vaccine comprises: an organic compound self-assembled from polylactic acid, porphyrin, or a porphyrin derivative, and a Co2+ ion conjugate; Sars-Cov-2 antigen protein; a vaccine adjuvant; and a lipid. The synthetic organic compound has an adjuvant encapsulated in its core and a Sars-Cov-2 antigen protein efficiently loaded on the surface, such that a nano-vaccine system allowing for co-delivery of the Sars-Cov-2 antigen protein and vaccine adjuvant is realized, thereby maximizing the immunogenicity of the Sars-Cov-2 recombinant subprotein and enabling tracking the distribution of the subprotein in an organism by means of fluorescent molecules. In addition, the nano-vaccine is also linked with a polypeptide that can specifically target antigen-presenting cells, so as to promote the uptake of the nano-vaccine by DC cells and promote anti-viral response. The preparation method is simple and efficient and provides a way for effectively preventing Sars-Cov-2 infection.

Resumen de: WO2023003608A1

Described herein are methods for the detection of a virus (e.g., SARS-CoV-2) RNA in dust, which can be used for continued environmental surveillance of the viral disease. Targeted monitoring of dust in high-concern buildings can complement broader population-level monitoring approaches. Additionally, a method for detection of a viral RNA in a dust sample is disclosed herein.

Resumen de: WO2023003332A1

The present invention relates to a plant-based COVID-19 variant recombinant spike protein expression vector, and a recombinant protein using the expression vector, wherein a plant expression system is used such that the recombinant protein does not have the disadvantages of animal-derived recombinant proteins and exhibits an excellent SARS coronavirus 2 prevention and treatment effect, and thus can be effectively utilized as a safe composition for preventing and treating COVID-19.

Resumen de: WO2023002944A1

[Problem] The present invention addresses the problem of providing a novel antibody that can prevent and/or treat SARS or COVID-19 infection.　Provided is an antibody which comprises heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:1, heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:2, heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:3, light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:4, light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:5, and light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:6 and which is capable of binding to a receptor binding domain (RBD) of S1 subunit of SARS-CoV or SARS-CoV-2, or an antibody fragment of the antibody.

Resumen de: WO2023002433A1

The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.

Resumen de: WO2023001080A1

Provided is a nucleic acid against novel corornavirus. The nucleic acid comprises a nucleic acid molecule SL capable of forming a stem-loop structure SL, which can target NSP1 after being transferred into a cell and inhibit protein synthesis of SARS-CoV-2, thereby inhibiting the replication of the virus. The stem-loop structure SL comprises 6 stem-loop segments SL1, SL2, SL3, SL4, SL4.5 and SL5 in total, or separate SL1, SL2, SL3, SL4, SL4.5 or SL5 nucleic acid molecules, or a stem-loop structure formed by means of connecting two or more of the 6 nucleic acid molecules in series. Further provided are a pharmaceutical composition of the nucleic acid and the use thereof in the preparation of a drug for preventing and/or treating SARS-CoV-2.

Resumen de: WO2023002505A1

The present invention relates to novel oligonucleotide sequences for rapid screening of epidemiologically important variants of SARS-CoV-2, wherein said oligonucleotide sequences acts as primers for amplification of sequences having Single-nucleotide polymorphisms (SNP)/mutations in the spike glycoprotein gene. The invention also relates to an assay for rapid screening of epidemiologically important variants of SARS-CoV-2 based upon using novel oligonucleotide sequences as primers. In particular, invention relates to oligonucleotide sequences of SEQ ID Nos. 1 - 37 for rapid screening of epidemiologically important variants of SARS-CoV-2.

Resumen de: WO2023004431A2

The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.

Resumen de: WO2023004415A2

Disclosed are compositions comprising a SARS-CoV-2 vaccine that can be administered orally. The vaccine can be on a platform comprising a spore coat protein from a spore forming bacteria, such as Bacillus subtilis. Also disclosed are methods of preventing or treating a COVID-19 infection comprising providing the SARS-CoV-2 vaccine to a subject.

Resumen de: WO2023004113A2

In alternative embodiments, provided are methods for eradicating or reducing the in vivo numbers of cancer stem cells comprising administering to an individual in need thereof an ADAR1 (adenosine deaminase associated with RNA1) inhibiting agent, wherein the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 Nano-luc reporter activity in cell lines and in human cancer stem cell assays. In alternative embodiments, provided are methods for inhibiting an RNA virus or a retrovirus, optionally a SARs-CoV-2 virus, comprising lentiviral ADAR1 overexpression and in vivo administration, optionally intravenous (IV) administration, of a lentiviral ADAR1 transduced stem cell, optionally the stem cell is a cord blood CD34+ cell or a mesenchymal stromal cell.

Resumen de: WO2023004010A2

Methods for diagnosing a subject for a COVID-19 infection state include collecting an alveolar air breath sample from a subject; passing the breath sample into contact with a volatile organic compound (VOC) sensor operable to detect a plurality of VOC biomarkers for a COVID-19 infection state; producing a readable sensor output for at least two of the plurality of biomarkers; and diagnosing the COVID-19 infection state of the subject based on the readable sensor output. Systems for detecting and identifying at least one VOC biomarker for a COVID-19 infection state in exhaled breath of a subject include a mouth piece connected to a housing, the mouth piece operable to receive the exhaled breath of the subject; a sensor module disposed in the housing, the sensor module operable to detect the at least one VOC biomarker in the exhaled breath, and further operable to produce a readable sensor output for the at least one VOC biomarker; and a communication module disposed in the housing and in communication with the sensor module, the communication module operable to transmit collected data from the sensor module.

Resumen de: US2023024722A1

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

Resumen de: US2023024012A1

Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions:wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

Resumen de: US2023023758A1

Disclosed is a multifunctional balloon dilatation catheter for intracorporeal membrane oxygenation, comprising: a catheter hub, a dilatation balloon, and M channels. The M channels comprise at least a balloon dilatation channel for dilating the narrowed part of the airway, a positioning & detection channel for positioning or detecting while inserting, a supply channel for continuous oxygen supply or drug administration to the patient, and a secretion removal channel for removing secretions from the airway. The catheter hub is a multi-channel connection device, through which the M channels are respectively connected to the external therapeutic devices of the catheter. The catheter is inserted into a bronchiole of the lungs. When using the catheter for emergency treatment of patients with pneumonia, especially COVID-19, measures such as airway dilatation, oxygen supply, sputum suction and biopsy can be simultaneously performed, thereby improving the survival rate of patients and reducing lung damage.

Resumen de: US2023024494A1

Sensitive detection of IgG antibodies against SARS-CoV-2 is important to assessing immune responses to viral infection or vaccination and immunity duration. Antibody assays using non-invasive body fluids such as saliva could facilitate mass testing including young children, elderly and those who resist blood draws, and easily allowing longitudinal testing/monitoring of antibodies over time. Here, we developed a new lateral flow (nLF) assay that sensitively detects SARS-CoV-2 IgG antibodies in the saliva samples of vaccinated individuals and previous COVID-19 patients. The 25 minutes nLF assay detected anti-spike protein (anti-S1) IgG in saliva samples with 100% specificity and high sensitivity from both vaccinated (99.51% for samples ≥19 days post 1st Pfizer or Moderna mRNA vaccine dose) and infected individuals. Antibodies against nucleocapsid protein (anti-NCP) was detected only in the saliva samples of COVID-19 patients and not in vaccinated samples, allowing facile differentiation of vaccination from infection. Salivary SARS-CoV-2 anti-S1 IgG antibodies correlated with that in matched dried blood spot (DBS) samples measured by a quantitative pGOLD™ lab-test, showing similar evolution trends post vaccination. The new salivary rapid test platform is applicable to non-invasive detection of antibodies against infection and vaccination for a wide range of diseases.

Resumen de: US2023025108A1

Described herein are diagnostic and control fusion protein reagents and methods for use thereof in simple rapid and inexpensive hemagglutinin assays for the detection of subject antibodies directed to the SARS-CoV-2 virus.

Resumen de: US2023022162A1

A method of treatment for coronavirus disease 2019 (COVID-19) is disclosed herein. The method comprises administering a therapeutically effective dose of a combination of ribavirin and minocycline. A pharmaceutical composition comprising ribavirin and minocycline is also disclosed herein. The pharmaceutical composition may further include one or more pharmaceutical excipients.

Resumen de: WO2023001814A1

The present invention concerns a composition comprising an Angiotensin receptor 1 (AT1) inhibitor and one or more other active compounds selected from the group consisting of antioxidants, caspase inhibitors, and mixtures thereof, for use as a drug in subjects in need thereof, for preventing and/or treating viral infections due to at least one betacoronavirus, in particular for preventing severe forms of viral infections due to betacoronavirus, in particular COVID-19 due to SARS-CoV-2.

Resumen de: WO2023001736A1

The present invention refers to a recombinant anti-SARS CoV-2 antibody with enhanced viral neutralization potency comprising an lgG3 constant and hinge region with one or more engineered glycans. The invention refers also to a nucleic acid encoding the anti-SARS CoV-2 antibody, plant cells expressing the anti-SARS CoV-2 antibodies, a method for production of anti-SARS CoV-2 antibody, and a pharmaceutical composition comprising anti-SARS CoV-2 antibody. The invention also refers to the use of an anti-SARS CoV-2 antibody for detecting SARS CoV-2 in a sample, the use for the manufacture of a medicament, and the use for treating or preventing diseases associated with coronavirus infections.

Resumen de: WO2023001999A1

The present invention relates to C2-thioether tryptophan (Trp) trimers and tetramers in which differently substituted thio aryl rings have been introduced at the C2 position of the indole ring of each T rp moiety. The invention also refers to their therapeutic use for the treatment or prevention of betacoronoavirus infections, mainly against SARS- CoV-2 infection.

Resumen de: US2023022109A1

Provided is a novel coronavirus vaccine using replication-deficient human type 5 adenovirus as a vector. The vaccine takes the replication-deficient human type 5 adenovirus that is lack of E1 and E3 in a combined mode as a vector, and HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and protective antigenic genes carried are optimized COVID-19 (SARS-CoV-2) S protein genes (Ad5-nCoV). The vaccine has good immunogenicity in both mouse and guinea pig models and can induce the body to produce a strong cellular and humoral immune responses in a short time. Research on the protective effect of hACE2 transgenic mice shows that 14 days after a single Ad5-nCoV immunization, the viral load in lung tissues can be significantly reduced. It shows that the vaccine has a good immune protection effect against COVID-19.

Resumen de: US2023021431A1

This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.

Resumen de: US2023022696A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline or thioxanthenone (or similar) structure which function as autophagy inhibitors and/or histone deactylase inhibitors, and their use as therapeutics for the treatment of conditions characterized with aberrant autophagy activity and/or aberrant HDAC activity (e.g., cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, aging, heart disease, rheumatoid arthritis, infectious diseases, conditions and symptoms caused by a viral infection (e.g., COVID-19)).